← The Wire
APGENasdaq
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · CIK 1974640
Apogee Therapeutics develops and researches programs, incurring significant operating losses
red 8-K · 90d🔥 High media attention
$6.66B
Market cap
$132.61
Last close
+0.1%
1D
+0.1%
5D
3.5M
Volume
Price · last 39 sessions+58.7%
May 4L $77.75 · H $132.88Jun 29
79
Total filings
Jun 26, 2026
Last filing
12/31
Fiscal year end
SC 13GSC 13GNov 14, 2024SC 13GSC 13GNov 8, 2024SC 13GSC 13GOct 22, 2024SC 13GSEC SCHEDULE 13GOct 4, 2024SC 13GSC 13GFeb 14, 2024SC 13GSC 13GNov 3, 2023SC 13GSC 13GAug 10, 2023SC 13GSC 13GJul 24, 2023
Insider Activity
In the 90 days to Mar 25, 2026: 4 sold $141.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Henderson JaneChief Financial Officer | Sell | 2,000 | $85.00 | $170K |
| Mar 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 8,363 | $74.29 | $621K |
| Mar 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 8,219 | $74.83 | $615K |
| Mar 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 3,418 | $75.86 | $259K |
| Mar 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 3,225 | $70.33 | $227K |
| Mar 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 2,075 | $71.98 | $149K |
| Mar 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 200 | $73.26 | $15K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 994 | $70.45 | $70K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 406 | $71.66 | $29K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 300 | $69.43 | $21K |
| Mar 2, 2026 | Henderson JaneChief Financial Officer | Sell | 300 | $68.27 | $20K |
| Feb 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 11,494 | $62.96 | $724K |
| Feb 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 7,551 | $63.73 | $481K |
| Feb 11, 2026 | Henderson Michael ThomasChief Executive Officer | Sell | 955 | $64.99 | $62K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 2,481 | $64.88 | $161K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 1,420 | $65.83 | $93K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 1,299 | $66.85 | $87K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 200 | $68.94 | $14K |
| Feb 4, 2026 | Dambkowski CarlChief Medical Officer | Sell | 100 | $67.88 | $7K |
| Feb 2, 2026 | Henderson JaneChief Financial Officer | Sell | 1,108 | $66.15 | $73K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 7 reputable articles.
Investor's Business DailyAbbVie Goes On The Offensive With $10.9 Billion Takeover7d agoBarron'sWhy AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising7d agoReutersAbbVie sharpens immunology focus with $10.9 billion Apogee deal7d agoBloomberg.comAbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash7d agoCNBCStocks making the biggest moves premarket: Apogee Therapeutics, SpaceX, Arcosa & more8d agoBarron'sS&P 500 Futures Fall in Premarket Trading; Apogee Therapeutics, Fervo Energy Lead8d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance